Latest News
-
Air India Enhances Operational Efficiency with New Crew Management System -
BlackRock Acquires Shares in Electrosteel Castings and PTC India for Rs 207 Crore -
IndiGo Enhances Domestic Routes with Direct Chennai-Durgapur Flights -
Tesla to Recall Nearly 4,000 Cybertrucks Over Accelerator Pedal Fault -
Reliance, ONGC, Tata, Adanis: Energy Stocks Didn't Get The Memo Of Bears, Up 12% In 30-Days; 10 Stocks To BUY -
Sebi to Enhance Price Discovery for Firms Trading Below Book Value -
Hindustan Zinc to Persist in Demerger Discussions with Government, Says CEO -
8 Tata Group Stocks To Buy That Will Pay Dividends Soon, Q4 In Focus; Are You Invested? -
Gold Prices In US: Yellow Metal Rates Surge Amid Escalating Tensions In Middle East; Hit Record High -
Jio Financial Services Sees 80% YoY Decline In Q4 Net Profit, Net Interest Income Dives 70%
AstraZeneca Shares Hit Upper Circuit on New Drug Launch
Shares of AstraZeneca hit upper circuit in the trade after the company announced that that it has launched FORXIGA, a breakthrough treatment for Type 2 diabetes mellitus.
The shares of the company were sen trading at Rs 1147 higher by 20 per cent on BSE.
FORXIGA belongs to a new class of Type 2 diabetes mellitus medication-a highly selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), the company said in the BSE filing.
It has a unique insulin independent mode of action that helps remove excess glucose from the body via urine which is associated with reductions in glycated haemoglobin (HbA1c), weight and systolic blood pressure, added further.
Globally, FORXIGA is the first medicine in the new SGLT2 inhibitor class to gain regulatory approval for the treatment of Type 2 diabetes mellitus.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.
GoodReturns.in
